Results 191 to 200 of about 595,039 (309)

A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer. [PDF]

open access: yesClin Cancer Res
Heumann TR   +27 more
europepmc   +1 more source

Medication Use and Risk of Microscopic Colitis: A Propensity‐Matched Analysis of US Adults ≥ 50 Years (2014–2024)

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Commonly prescribed NSAIDs, PPIs and SSRIs were associated with a higher risk of microscopic colitis after propensity score matching, whereas ACE inhibitors, ARBs and statins showed no significant association. ABSTRACT Background The association between medications—including non‐steroidal anti‐inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs ...
Yassine Kilani   +6 more
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort

open access: yesCancer Science, EarlyView.
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai   +16 more
wiley   +1 more source

Risk Factors for Peritonitis Associated With Endoscopic Ultrasound-guided Hepaticogastrostomy. [PDF]

open access: yesDEN Open
Sato J   +11 more
europepmc   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

open access: yesCancer Science, EarlyView.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe   +5 more
wiley   +1 more source

Remnant Cystic Duct Carcinoma Mimicking Duodenal Carcinoma after Cholecystectomy: A Case Report. [PDF]

open access: yesSurg Case Rep
Okura T   +9 more
europepmc   +1 more source

Mucinous Cystic Neoplasms of the Liver and Extrahepatic Biliary Tract [PDF]

open access: yes, 2018
Dzeina Mezale   +7 more
openaire   +1 more source

Home - About - Disclaimer - Privacy